News

News and Press Releases
About the CF Foundation | CFTR Modulators CF Therapy Kalydeco Receives Approval in the European Union

The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.

| 1 min read
About the CF Foundation | Public Policy Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives

Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs

| 5 min read
About the CF Foundation | CFTR Modulators Kalydeco Receives Recommendation for Approval in the European Union

The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.

| 2 min read